File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Medical treatment of viral pneumonia including SARS in immunocompetent adult

TitleMedical treatment of viral pneumonia including SARS in immunocompetent adult
Authors
KeywordsImmunocompetent host
SARS
Treatment
Viral pneumonia
Issue Date2004
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/jinf
Citation
Journal Of Infection, 2004, v. 49 n. 4, p. 262-273 How to Cite?
AbstractSince no randomized controlled trials have been conducted on the treatment of viral pneumonia by antivirals or immunomodulators in immunocompetent adults, a review of such anecdotal experience are needed for the more rational use of such agents. Case reports (single or case series) with details on their treatment and outcome in the English literature can be reviewed for pneumonia caused by human or avian influenza A virus (50 patients), varicella zoster virus (120), adenovirus (29), hantavirus (100) and SARS coronavirus (SARS-CoV) (841). Even with steroid therapy alone, the mortality rate appeared to be lower when compared with conservative treatment for pneumonia caused by human influenza virus (12.5% vs. 42.1%) and hantavirus (13.3% vs. 63.4%). Combination of an effective antiviral, acyclovir, with steroid in the treatment of varicella zoster virus may be associated with a lower mortality than acyclovir alone (0% vs. 10.3%). Combination of interferon alfacon-1 plus steroid, or lopinavir/ritonavir, ribavirin plus steroid were associated with a better outcome than ribavirin plus steroid (0% vs. 2.3% vs. 7.7%, respectively). Combination of lopinavir/ritonavir plus ribavirin significantly reduced the virus load of SARS-CoV in nasopharyngeal, serum, stool and urine specimens taken between day 10 and 15 after symptom onset when compared with the historical control group treated with ribavirin. It appears that the combination of an effective antiviral and steroid was associated with a better outcome. Randomized therapeutic trial should be conducted to ascertain the relative usefulness of antiviral alone or in combination with steroid. © 2004 The British Society. Published by Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/48634
ISSN
2015 Impact Factor: 4.382
2015 SCImago Journal Rankings: 2.070
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheng, VCCen_HK
dc.contributor.authorTang, BSFen_HK
dc.contributor.authorWu, AKLen_HK
dc.contributor.authorChu, CMen_HK
dc.contributor.authorYuen, KYen_HK
dc.date.accessioned2008-05-22T04:19:37Z-
dc.date.available2008-05-22T04:19:37Z-
dc.date.issued2004en_HK
dc.identifier.citationJournal Of Infection, 2004, v. 49 n. 4, p. 262-273en_HK
dc.identifier.issn0163-4453en_HK
dc.identifier.urihttp://hdl.handle.net/10722/48634-
dc.description.abstractSince no randomized controlled trials have been conducted on the treatment of viral pneumonia by antivirals or immunomodulators in immunocompetent adults, a review of such anecdotal experience are needed for the more rational use of such agents. Case reports (single or case series) with details on their treatment and outcome in the English literature can be reviewed for pneumonia caused by human or avian influenza A virus (50 patients), varicella zoster virus (120), adenovirus (29), hantavirus (100) and SARS coronavirus (SARS-CoV) (841). Even with steroid therapy alone, the mortality rate appeared to be lower when compared with conservative treatment for pneumonia caused by human influenza virus (12.5% vs. 42.1%) and hantavirus (13.3% vs. 63.4%). Combination of an effective antiviral, acyclovir, with steroid in the treatment of varicella zoster virus may be associated with a lower mortality than acyclovir alone (0% vs. 10.3%). Combination of interferon alfacon-1 plus steroid, or lopinavir/ritonavir, ribavirin plus steroid were associated with a better outcome than ribavirin plus steroid (0% vs. 2.3% vs. 7.7%, respectively). Combination of lopinavir/ritonavir plus ribavirin significantly reduced the virus load of SARS-CoV in nasopharyngeal, serum, stool and urine specimens taken between day 10 and 15 after symptom onset when compared with the historical control group treated with ribavirin. It appears that the combination of an effective antiviral and steroid was associated with a better outcome. Randomized therapeutic trial should be conducted to ascertain the relative usefulness of antiviral alone or in combination with steroid. © 2004 The British Society. Published by Elsevier Ltd. All rights reserved.en_HK
dc.format.extent103713 bytes-
dc.format.extent1902 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/jinfen_HK
dc.relation.ispartofJournal of Infectionen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectImmunocompetent hosten_HK
dc.subjectSARSen_HK
dc.subjectTreatmenten_HK
dc.subjectViral pneumoniaen_HK
dc.titleMedical treatment of viral pneumonia including SARS in immunocompetent adulten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0163-4453&volume=49&issue=4&spage=262&epage=273&date=2004&atitle=Medical+treatment+of+viral+pneumonia+including+SARS+in+immunocompetent+adult.en_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturepostprinten_HK
dc.identifier.doi10.1016/j.jinf.2004.07.010en_HK
dc.identifier.pmid15474623-
dc.identifier.scopuseid_2-s2.0-5044241481en_HK
dc.identifier.hkuros100183-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-5044241481&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume49en_HK
dc.identifier.issue4en_HK
dc.identifier.spage262en_HK
dc.identifier.epage273en_HK
dc.identifier.isiWOS:000224665600002-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridCheng, VCC=23670479400en_HK
dc.identifier.scopusauthoridTang, BSF=8908243000en_HK
dc.identifier.scopusauthoridWu, AKL=7402998681en_HK
dc.identifier.scopusauthoridChu, CM=7404345558en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats